Slipped Capital Femoral Epiphysis Associated with Endocrinopathy: A Narrative Review

K Aaron Shaw; A Luke Shiver; Tannur Oakes; Nicholas D Fletcher

doi:10.2106/JBJS.RVW.21.00188

Slipped Capital Femoral Epiphysis Associated with Endocrinopathy: A Narrative Review

JBJS Rev. 2022 Feb 7;10(2). doi: 10.2106/JBJS.RVW.21.00188.

Authors

K Aaron Shaw¹, A Luke Shiver², Tannur Oakes¹, Nicholas D Fletcher³

Affiliations

¹ Dwight D. Eisenhower Army Medical Center, Fort Gordon, Georgia.
² Medical College of Georgia at Augusta University, Augusta, Georgia.
³ Children's Healthcare of Atlanta/Emory University, Atlanta, Georgia.

PMID: 35130197
DOI: 10.2106/JBJS.RVW.21.00188

Abstract

»: Slipped capital femoral epiphysis (SCFE) has a well-documented association with underlying endocrine conditions, including thyroid hormone aberrations and parathyroid dysfunction.

»: Recombinant growth hormone therapy has also been identified as a risk factor for the development of SCFE.

»: Presentation before their 10th birthday or after their 16th birthday along with height of <10th percentile are reliable risk factors for identifying children with an SCFE who are at a heightened risk for an underlying endocrinopathy and can been used to guide selective laboratory testing.

»: Patients with unilateral SCFE presentations with an underlying endocrinopathy are at a heightened risk for contralateral slip development and should be treated with prophylactic fixation.

Publication types

Review

MeSH terms

Child
Endocrine System Diseases*
Humans
Risk Factors
Slipped Capital Femoral Epiphyses* / complications
Slipped Capital Femoral Epiphyses* / diagnostic imaging
Slipped Capital Femoral Epiphyses* / surgery